Chaetocin: A review of its anticancer potentials and mechanisms
Open Access
- 1 November 2021
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 910, 174459
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin AJournal of Korean Medical Science, 2013
- The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferationBritish Journal of Cancer, 2011
- Apoptosis in cancer: from pathogenesis to treatmentJournal of Experimental & Clinical Cancer Research, 2011
- XPB, a subunit of TFIIH, is a target of the natural product triptolideNature Chemical Biology, 2011
- p21WAF1 gene promoter is epigenetically silenced by CTIP2 and SUV39H1Oncogene, 2009
- The Anticancer Agent Chaetocin Is a Competitive Substrate and Inhibitor of Thioredoxin ReductaseAntioxidants & Redox Signaling, 2009
- The role of hypoxia-inducible factors in tumorigenesisCell Death & Differentiation, 2008
- Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stressBlood, 2006
- Different mitochondrial intermembrane space proteins are released during apoptosis in a manner that is coordinately initiated but can vary in durationProceedings of the National Academy of Sciences, 2006
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004